EGFR and non-small cell lung carcinoma: Erlotinib in combination with bevacizumab was shown in the JO25567 study to improve progression-free survival (PFS) in patients with epidermal growth factor receptor–mutated (EGFR-mutated) advanced non–small-cell lung cancer (NSCLC) compared with treatment with erlotinib alone1.